The juvenile Dermatomyositis belongs to the rheumatic diseases of connective tissue, which are also called collagenoses. The disease is relatively rare, it is estimated that about three out of every one million children get new in year. Girls are twice as likely to be affected as boys.
Methotrexate (MTX) is a chemo agent and is used as a basic therapy in many of the 400 different rheumatic diseases, as well as in rheumatoid arthritis.
Already in this topic we talked about the treatment method. MTX is also used in combination with Prednisone at JDM. The first therapy option for juvenile dermatomyositis seems to show good results, as the latest Five-Year Single-Blind study shows
#juvenile dermatomyositis #JDM #immunosuppressive drugs #PRINTO #A versus Prednisone plus Methotrexate #muscle weakness